ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

Capitol Hill: Senate bill would allow sale of therapies for catastrophic illness after phase I trials.

December 2, 2005

In Brief: NCI Needs To Move Quicker On Funding Jot New Leads, Rauscher Says; Harley Dirks Quits

October 15, 1976

In Brief: Thomas, Murray share Nobel Prize for Medicine; Wynder To Present Carese Memorial Lecture

October 12, 1990

Possible Budget Balancing Effort Darkens Prospect For Increase In Cancer Budget

March 7, 1980

Medicare Covers All PET Scans For Cancer In New Program

May 26, 2006

Gynecologic Oncology Group To Conduct Phase III Trial of Xyotax For Ovarian Cancer

April 30, 2004